menu
    • menu

    Company profile for Bora Pharmaceuticals

    Bora Pharmaceuticals-PSE
    News
    Bora to Expand Rare Disease Portfolio with Acquisition of Pyros

    26 Oct 2024

    // PRESS RELEASE

    Bora Pharmaceuticals Appoints Division President of CDMO Business

    04 Oct 2024

    // PRESS RELEASE

    Formosa Ships APP13007 To US For Commercialization

    09 Sep 2024

    // PR NEWSWIRE

    DATA COMPILATION
    #PharmaFlow

    Bora Pharmaceuticals

    Contact Supplier

    Website

    Medlab Asia & Asia Health

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/2wvnSDggkmU

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Bora Pharmaceuticals- Making success more certain.

    Related CompaniesRelated Companies

    About

    Bora Pharmaceuticals is a premier global contract development and manufacturing organization (CDMO), specializing in formulation development, clinical and commercial manufacturing and packaging of complex oral solid dose, liquid, and semi-solid pharmaceutical products for clinical and commercial uses.
    From cell-line development and formulation to analytical services and clinical cGMP manufacturing, Bora now provides tailored development and manufacturing services to biologics developers. Bora operates nine cGMP manufacturing sites in Asia, Canada, and the United States, and delivers to over 100 markets worldwide.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bora PharmaceuticalsTaiwan Flag
    Country
    Country
    Taiwan
    Address
    Address
    6F, No 69, Xing'ai Road, Neihu District, Taipei City 114
    Telephone
    Telephone
    +1 844636-BORA (2672) // +1 616636-BORA (2672)
    Client Email
    Email
    marketing@bora-corp.com
    Client Website
    Website
    https://www.boracdmo.com
    Linkedin
    Linkedin
    https://in.linkedin.com/company/borapharmaceuticals
    youtube
    YouTube
    http://www.youtube.com/@groupbora5676
    Twitter
    Twitter
    Contact Info
    Others

    North America facility:
    Bora Pharmaceuticals – North America

    Taiwan facilities:
    Bora Pharmaceuticals – Taoyuan
    Bora Pharmaceuticals – Tainan
    Bora Pharmaceuticals – Zhongli
    Bora Pharmaceuticals – Zhunan
    Bora Biologics – Zhubei

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    CPHI Middle east

    CPHI Middle east

    Not Confirmed

    envelop Contact Supplier

    CPHI Middle east

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Ophthalmics

    read-more

      https://www.pharmacompass.com/pdf/party/content/bora-pharmaceuticals-party-content-78018.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Facilities in Taiwan

    read-more

      https://www.pharmacompass.com/pdf/party/content/bora-pharmaceuticals-party-content-2455.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Cell Line Development

    read-more

      https://www.pharmacompass.com/pdf/party/content/bora-pharmaceuticals-party-content-24295.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Outstanding Company of the Year Award at Bio-Asia Taiwan 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/bora-pharmaceuticals-party-content-468.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Biologics CDMO

    read-more

      https://www.pharmacompass.com/pdf/party/content/bora-pharmaceuticals-party-content-76291.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Small Molecule CDMO

    read-more

      https://www.pharmacompass.com/pdf/party/content/bora-pharmaceuticals-party-content-99313.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Bora new CMO for Commercial Manufacturing of Phexxi® for Evofem

    read-more

      https://www.pharmacompass.com/pdf/party/content/bora-pharmaceuticals-party-content-1652425950.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Extrusion-Spheronization for Controlled Release Forms

    read-more

      https://www.pharmacompass.com/pdf/party/content/bora-pharmaceuticals-party-content-1627541387.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2918

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities

    #PharmaFlow by PHARMACOMPASS
    08 Aug 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Bora to Expand Rare Disease Portfolio with Acquisition of Pyros
    Bora to Expand Rare Disease Portfolio with Acquisition of Pyros

    26 Oct 2024

    // PRESS RELEASE

    https://bora-corp.com/bora-pharmaceuticals-to-expand-rare-disease-portfolio-with-acquisition-of-us-based-pyros-pharmaceuticals/

    PRESS RELEASE
    26 Oct 2024
    Share Share
    Bora Pharmaceuticals Appoints Division President of CDMO Business
    Bora Pharmaceuticals Appoints Division President of CDMO Business

    04 Oct 2024

    // PRESS RELEASE

    https://bora-corp.com/bora-appoints-j-d-mowery-as-first-division-president-of-its-cdmo-business/

    PRESS RELEASE
    04 Oct 2024
    Share Share
    Formosa Ships APP13007 To US For Commercialization
    Formosa Ships APP13007 To US For Commercialization

    09 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-makes-first-shipment-of-app13007-clobetasol-propionate-ophthalmic-suspension-0-05-to-the-united-states-for-commercialization-302241470.html

    PR NEWSWIRE
    09 Sep 2024
    Share Share
    Tanvex Appoints Biopharma Industry Veteran Stephen Lam as CEO
    Tanvex Appoints Biopharma Industry Veteran Stephen Lam as CEO

    05 Sep 2024

    // PRESS RELEASE

    https://bora-corp.com/tanvex-appoints-biopharma-industry-veteran-stephen-lam-as-ceo/

    PRESS RELEASE
    05 Sep 2024
    Share Share
    Bora Pharma Invests In Tanvex To Expand Global Biomanufacturing Services
    Bora Pharma Invests In Tanvex To Expand Global Biomanufacturing Services

    27 Aug 2024

    // PRESS RELEASE

    https://bora-corp.com/bora-completes-acquisition-of-us-sterile-fill-finish-facility-from-emergent/

    PRESS RELEASE
    27 Aug 2024
    Share Share
    Bora Completes Acquisition of US Sterile Fill/Finish Facility From Emergent
    Bora Completes Acquisition of US Sterile Fill/Finish Facility From Emergent

    21 Aug 2024

    // PRESS RELEASE

    https://bora-corp.com/bora-completes-acquisition-of-us-sterile-fill-finish-facility-from-emergent/

    PRESS RELEASE
    21 Aug 2024
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothBora Pharmaceuticals- Making success more certain.

    Bora Expands Rare Disease Portfolio with Pyros Pharma Acquisition

    Details:

    Through the acquisition of US-based Pyros, Bora will expand his pipelines by adding some candidates such as Vigafyde (vigabatrin), which is indicated for the treatment of infantile spasms.


    Lead Product(s): Vigabatrin

    Therapeutic Area: Neurology Brand Name: Vigafyde

    Study Phase: ApprovedProduct Type: Small molecule

    Recipient: Pyros Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition October 25, 2024

    Bora Pharmaceutical

    01

    Bora Pharmaceuticals

    Taiwan
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothBora Pharmaceuticals- Making success more certain.

    Lead Product(s) : Vigabatrin

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Recipient : Pyros Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Bora Expands Rare Disease Portfolio with Pyros Pharma Acquisition

    Details : Through the acquisition of US-based Pyros, Bora will expand his pipelines by adding some candidates such as Vigafyde (vigabatrin), which is indicated for the treatment of infantile spasms.

    Brand Name : Vigafyde

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    October 25, 2024

    Bora Pharmaceutical

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothBora Pharmaceuticals- Making success more certain.

    Bora Pharmaceuticals Completes Acquisition of Upsher-Smith

    Details:

    Through the acquisition, Bora will commercialize Amantadine HCl-Generic, which is an NMDA receptor inhibitor. It is indicated for the treatment of influenza A infections and Parkinsonism.


    Lead Product(s): Amantadine Hydrochloride

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Amantadine HCl-Generic

    Study Phase: ApprovedProduct Type: Small molecule

    Recipient: Upsher-Smith Laboratories

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition April 01, 2024

    Bora Pharmaceutical

    02

    Bora Pharmaceuticals

    Taiwan
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothBora Pharmaceuticals- Making success more certain.

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Recipient : Upsher-Smith Laboratories

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Bora Pharmaceuticals Completes Acquisition of Upsher-Smith

    Details : Through the acquisition, Bora will commercialize Amantadine HCl-Generic, which is an NMDA receptor inhibitor. It is indicated for the treatment of influenza A infections and Parkinsonism.

    Brand Name : Amantadine HCl-Generic

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    April 01, 2024

    Bora Pharmaceutical

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothBora Pharmaceuticals- Making success more certain.

    CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M

    Details:

    Bora acquires Upsher-Smith’s product portfolio, including Amantadine hydrochloride for treating influenza A virus infections.


    Lead Product(s): Amantadine Hydrochloride

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Amantadine HCl-Generic

    Study Phase: ApprovedProduct Type: Small molecule

    Recipient: Upsher-Smith Laboratories

    Deal Size: $210.0 million Upfront Cash: Undisclosed

    Deal Type: Acquisition January 18, 2024

    Bora Pharmaceutical

    03

    Bora Pharmaceuticals

    Taiwan
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothBora Pharmaceuticals- Making success more certain.

    Lead Product(s) : Amantadine Hydrochloride

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Recipient : Upsher-Smith Laboratories

    Deal Size : $210.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M

    Details : Bora acquires Upsher-Smith’s product portfolio, including Amantadine hydrochloride for treating influenza A virus infections.

    Brand Name : Amantadine HCl-Generic

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    January 18, 2024

    Bora Pharmaceutical

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothBora Pharmaceuticals- Making success more certain.

    Bora and Celltrion Join Forces To Distribute Oral Drugs Across APAC

    Details:

    Under the partnership, Bora will manufacture and commercialize a range of oral dosage form drugs (OSD), including CT-G20, a hypertrophic cardiomyopathy treatment candidate, across the APAC region.


    Lead Product(s): CT-G20

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CT-G20

    Study Phase: Phase IProduct Type: Small molecule

    Sponsor: Celltrion

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership April 06, 2023

    Bora Pharmaceutical

    04

    Bora Pharmaceuticals

    Taiwan
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothBora Pharmaceuticals- Making success more certain.

    Lead Product(s) : CT-G20

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Celltrion

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Bora and Celltrion Join Forces To Distribute Oral Drugs Across APAC

    Details : Under the partnership, Bora will manufacture and commercialize a range of oral dosage form drugs (OSD), including CT-G20, a hypertrophic cardiomyopathy treatment candidate, across the APAC region.

    Brand Name : CT-G20

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    April 06, 2023

    Bora Pharmaceutical

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothBora Pharmaceuticals- Making success more certain.

    Bora Pharmaceuticals Partners with TaiRx

    Details:

    CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific factors.


    Lead Product(s): Foslinanib,Sorafenib

    Therapeutic Area: Oncology Brand Name: CVM-1118

    Study Phase: Phase IIProduct Type: Small molecule

    Sponsor: TaiRx

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership September 27, 2022

    Bora Pharmaceutical

    05

    Bora Pharmaceuticals

    Taiwan
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothBora Pharmaceuticals- Making success more certain.

    Lead Product(s) : Foslinanib,Sorafenib

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : TaiRx

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Bora Pharmaceuticals Partners with TaiRx

    Details : CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific fact...

    Brand Name : CVM-1118

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    September 27, 2022

    Bora Pharmaceutical

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothBora Pharmaceuticals- Making success more certain.

    Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Ph...

    Details:

    Initially, Bora will manufacture Phexxi for nations currently considering formal regulatory approval of Phexxi (L-lactic Acid), for the prevention of pregnancy, including Mexico and Nigeria.


    Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate

    Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Phexxi

    Study Phase: ApprovedProduct Type: Small molecule

    Recipient: Evofem Biosciences

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership May 10, 2022

    Bora Pharmaceutical

    06

    Bora Pharmaceuticals

    Taiwan
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothBora Pharmaceuticals- Making success more certain.

    Lead Product(s) : L-Lactic Acid,Citric Acid,Potassium Bitartrate

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Highest Development Status : Approved

    Recipient : Evofem Biosciences

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmace...

    Details : Initially, Bora will manufacture Phexxi for nations currently considering formal regulatory approval of Phexxi (L-lactic Acid), for the prevention of pregnancy, including Mexico and Nigeria.

    Brand Name : Phexxi

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    May 10, 2022

    Bora Pharmaceutical

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothBora Pharmaceuticals- Making success more certain.

    KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic Product for Filing in Japan

    Details:

    Upon PMDA’s approval, Bora will be the commercial manufacturing site for the generic product production. Bora Pharmaceuticals’ sites already have an excellent track record with many regulatory agencies around the world.


    Lead Product(s): Undisclosed

    Therapeutic Area: Technology Brand Name: Undisclosed

    Study Phase: UndisclosedProduct Type: Undisclosed

    Recipient: Kyowa Pharmaceutical Industry

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership August 05, 2021

    Bora Pharmaceutical

    07

    Bora Pharmaceuticals

    Taiwan
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothBora Pharmaceuticals- Making success more certain.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Technology

    Highest Development Status : Undisclosed

    Recipient : Kyowa Pharmaceutical Industry

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic P...

    Details : Upon PMDA’s approval, Bora will be the commercial manufacturing site for the generic product production. Bora Pharmaceuticals’ sites already have an excellent track record with many regulatory agencies around the world.

    Brand Name : Undisclosed

    Molecule Type : Undisclosed

    Upfront Cash : Undisclosed

    August 05, 2021

    Bora Pharmaceutical

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Services

    Discover the service capabilities from this company

    Analytical

    Discover their expertise for : Analytical

    Drug Product Manufacturing

    Discover their expertise for : Drug Product Manufacturing

    Packaging

    Discover their expertise for : Packaging

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Bora Pharmaceuticals full-view
    In-Vitro Bioequivalence studies
    full-view
    Topical Solutions
    full-view
    Formulation Development Services for Solution
    full-view
    Ophthalmic Formulations
    full-view
    Manufacturing Vaccines
    full-view
    Multidose Eye Drops Manufacturing
    full-view
    Nasal Care Products Range
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    Others

    read-more
    read-more

    01

    Inspected

    RoW
    Medlab Asia & Asia Health
    Not Confirmed

    Bora Pharmaceuticals

    Inspection : Health Canada

    About the Company : Bora Pharmaceuticals is a premier global contract development and manufacturing organization (CDMO),...

    Bora Pharmaceuticals is a premier global contract development and manufacturing organization (CDMO), specializing in formulation development, clinical and commercial manufacturing and packaging of complex oral solid dose, liquid, and semi-solid pharmaceutical products for clinical and commercial uses.
    From cell-line development and formulation to analytical services and clinical cGMP manufacturing, Bora now provides tailored development and manufacturing services to biologics developers. Bora operates nine cGMP manufacturing sites in Asia, Canada, and the United States, and delivers to over 100 markets worldwide.

    Country : Taiwan

    Bora Pharmaceutical

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search